JAMA Network
About The Study: In this post hoc pooled analysis of 13,194 patients with chronic heart failure (HF) in the PARADIGM-HF and PARAGON-HF randomized clinical trials, sacubitril/valsartan significantly reduced hospitalization for any reason, with benefits most apparent in patients with a left ventricular ejection fraction below normal. This reduction appeared to be principally driven by lower rates of cardiac and pulmonary hospitalizations.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
